Phaseline

Companies › Suzhou Immunofoco Biotechnology

Suzhou Immunofoco Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMC002
anti-CLDN18.2 CAR-T cell therapy
CLDN18Phase 3Gastric AdenocarcinomaMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07103668IMC002Phase 3Gastric AdenocarcinomaOncologyMay 2027

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

LaNova Medicines Zhejiang FutureGen Biopharmaceutical (Beijing) NingBo Junyan Hongshi Biosciences Biokin (Shanghai) Biopharmaceutical I-Mab Biopharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.